Science and technology company Battelle disclosed on Monday that Dr Wayne A I Frederick, current president of Howard University and the Charles R Drew Professor of Surgery, has been elected to the Battelle board of directors.
Dr Frederick will initially serve in an advisory role and will become a full voting member on the company's board in 2022.
Following post-doctoral research and surgical oncology fellowships at the University of Texas MD Anderson Cancer Center, Dr Frederick began his academic career as associate director of the cancer center at the University of Connecticut. He was appointed the seventeenth president of Howard University in 2014 and has been responsible for advancing the university's commitment to student opportunity, academic innovation, public service, and fiscal stability. He previously served as provost and chief academic officer.
Currently, Dr Frederick serves on the board of directors for the Federal Reserve Bank of Richmond and Humana Inc.
Headquartered in Columbus, Ohio and founded in 1929, Battelle conducts research and development, designs and manufactures products, and delivers critical services for government and commercial customers. Battelle also supports science, technology, engineering and mathematics (STEM) education.
Tri-City Cardiology adds new members to care team
ABL Bio receives upfront payment and equity investment from Eli Lilly
Harbour BioMed and Yantai Lannacheng Biotechnology form collaboration to advance next-gen RDCs
Repare Therapeutics sells RP-3467 asset to Gilead Sciences for up to USD30m
Sanofi agrees USD2.2bn acquisition of Dynavax to strengthen adult vaccine portfolio
Sanofi and Regeneron's Dupixent gains Japan approval for paediatric asthma patients aged 6 to 11
Aqualung Therapeutics' Phase 2a lung fibrosis study approved by US FDA
Faron launches BLAZE trial with Institute of Cancer Research to address immunotherapy resistance
Alvotech launches first-in-market golimumab biosimilar in Europe
AstraZeneca secures US Breakthrough status for Enhertu in early breast cancer
GSK agrees US pricing framework to expand access to respiratory medicines
ECO Animal Health Group secures EU approval for ECOVAXXIN MS
Century Health partnerss with Tessel Biosciences to advance early drug development in COPD
Curasight reports first patient dosed in Phase 1 uTREAT trial in brain cancer